(ATN) Aerosol Pentamidine: The Need For Advocacy

DonateNow
Print this article

(ATN) Aerosol Pentamidine: The Need For Advocacy

AIDS TREATMENT NEWS No. 056 - May 6, 1988
John S. James


Ryan White, diagnosed with AIDS three years ago at age 13, has become well known to the nation through media coverage of his situation. White, exposed to AIDS through a hemophilia treatment, was banned from the local school and forced by prejudice to move from Kokomo, Indiana to Arcadia, Indiana, where he and his family found acceptance. Three years ago, doctors predicted he had six months to live.

In January 1988 Ryan White was hospitalized for a recurrence of pneumocystis. Michael Callen, co-founder of the People With AIDS Coalition in New York, called White's family to make sure they knew about aerosol pentamidine. It turned out that the family had not been told about that treatment, or any other preventive for pneumocystis.

Callen sent a packet of information for the physician. Ryan White is now using aerosol pentamidine and doing well.

It surprises us that even in so well known a case, the family was not told about the option of pneumocystis prophylaxis. While not formally approved by the FDA--due to research delays like those cited above--prophylaxis by aerosol pentamidine or other treatments has become the standard of care of experienced AIDS physicians. An editorial in the New England Journal of Medicine (October 15, 1987) recommended it for those at risk for pneumocystis.

Note: Michael Callen, a well-known singer as well as AIDS activist, was diagnosed six years ago and not expected to live past 1984. He is very much alive and just released his first solo album, Purple Heart, a collection of songs about being gay in the age of AIDS. Purple Heart is available through Significant Other Records, P.O. Box 1545, Canal Street Station, New York, NY 10013.


880506
ATN05603


Copyright © 1988 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org  http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .